Teprotumumab associated menstrual changes
Menstrual changes occurred in 55% of menstruating females receiving teprotumumab therapy. The most common changes were amenorrhea and oligomenorrhea. The majority of patients regained normal menstruation after cessation of therapy. It is important for providers to be aware of this potential adverse event when treating menstruating women with TED.
Authors
- Andrea L. Kossler (ORCID: https://orcid.org/0000-0003-3110-1210)
- Patrick J. Hunt (ORCID: https://orcid.org/0000-0003-0051-6667)
- Amina Malik
- Karina Richani (ORCID: https://orcid.org/0000-0002-1966-2675)
- Roman Shinder
- Hila Goldberg (ORCID: https://orcid.org/0000-0002-6062-1066)
- Cornelius Rosenbaum (ORCID: https://orcid.org/0000-0002-4769-181X)
- Tracy Lu
Institutions
- Texas Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- SUNY Downstate Health Sciences University (US)
- Cornell University (US)
- American Society of Plastic Surgeons (US)
- Methodist Hospital (US)
- National Student Clearinghouse Research Center (US)
- Weill Cornell Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- Orbit
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1080/01676830.2025.2609906
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00